Venetoclax plus daunorubicin and cytarabine in newly diagnosed acute myeloid leukemia patients: A propensity score-matched analysis.

导出 LinkOut

翻译打印收藏纠错

作者： Rong,Wang ^[1] ; Yi,Zhang ^[2] ; Jie,Chang ^[1] ; Huafeng,Wang ^[2] ; Yinjun,Lou ^[3] ; Min,Yang ^[1] ; Gaixiang,Xu ^[2] ; Hongyan,Tong ^[1] ; Wanzhuo,Xie ^[2] ; De,Zhou ^[3] ; Juying,Wei ^[1] ; Wenyuan,Mai ^[2] ; Xiujin,Ye ^[3] ; Haitao,Meng ^[1] ; Jie,Jin ^[2] ; Hong-Hu,Zhu ^[3]

作者单位： Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. ^[1] Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China. ^[2] Zhejiang University Cancer Center, Hangzhou, Zhejiang, China. ^[3] Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, Zhejiang, China. ^[4] Liangzhu Laboratory, Zhejiang University, Hangzhou, Zhejiang, China. ^[5]

关键词 acute myeloid leukemia propensity score-matched analysis venetoclax

主题词青年人(Young Adult);人类(Humans);倾向性评分(Propensity Score);白血病, 髓样, 急性(Leukemia, Myeloid, Acute);柔红霉素(Daunorubicin);阿糖胞苷(Cytarabine);磺胺类(Sulfonamides)

DOI 10.1002/hon.3260

PMID 38415873

发布时间 2024-02-29

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交